港股異動丨歐舒丹(0973.HK)續升6.7% 兩日大漲近20% 績後獲投行看好
格隆匯12月2日丨歐舒丹(0973.HK)續升6.72%,績後兩日大漲近20%。現報19.7港元創1年新高價,暫成交1558萬港元,總市值291億港元。歐舒丹11月30日公佈,中期盈利降37.53%至1561.3萬歐元,不派息。集團的財務狀況維持穩健。自由現金流量上升2840萬歐元至約1.08億歐元,而淨債務減少約2.07億歐元至約6.99億歐元。花旗調高歐舒丹目標價至19港元和維持買入評級,以及升公司未來三年盈測,以反映公司較高經營溢利率預期;野村績後也上調歐舒丹目標價至21.1港元及重申買入評級,以反映公司利潤率前景樂觀。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.